The Clinical Effectiveness of 311C90 in the Acute Treatment of Migraine
作者:
Michel D. Ferrari,
期刊:
European Neurology
(Karger Available online 1996)
卷期:
Volume 36,
issue 2
页码: 4-7
ISSN:0014-3022
年代: 1996
DOI:10.1159/000119096
出版商: S. Karger AG
关键词: 311C90;Headache response;Headache recurrence;Efficacy
数据来源: Karger
摘要:
Efficacy with currently marketed antimigraine compounds is less than optimal. 311C90 is a novel and selective 5-HT1D receptor agonist in development for the acute treatment of migraine. It shows evidence of both central and peripheral activity within the trigemino-vascular system and it is rapidly absorbed following oral administration. In clinical studies in migraine patients, a headache response at 2 hours has been observed in 65–81% of patients at doses above 1 mg. Favourable response rates are reported as early as 1 hour post-dose and efficacy rates continue to improve up to 4 hours. Headache recurrence is reported by 25-35% of patients and 311C90 is also effective in relieving the non-headache symptoms of migrain
点击下载:
PDF
(567KB)
返 回